BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 26390965)

  • 1. EphB4 inhibitor overcome the acquired resistance to cisplatin in melanomas xenograft model.
    Yang X; Yang Y; Tang S; Tang H; Yang G; Xu Q; Wu J
    J Pharmacol Sci; 2015 Sep; 129(1):65-71. PubMed ID: 26390965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin regulates the MAPK kinase pathway to induce increased expression of DNA repair gene ERCC1 and increase melanoma chemoresistance.
    Li W; Melton DW
    Oncogene; 2012 May; 31(19):2412-22. PubMed ID: 21996734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin.
    Leonetti C; Biroccio A; Candiloro A; Citro G; Fornari C; Mottolese M; Del Bufalo D; Zupi G
    Clin Cancer Res; 1999 Sep; 5(9):2588-95. PubMed ID: 10499637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Senescence-associated secretory factors induced by cisplatin in melanoma cells promote non-senescent melanoma cell growth through activation of the ERK1/2-RSK1 pathway.
    Sun X; Shi B; Zheng H; Min L; Yang J; Li X; Liao X; Huang W; Zhang M; Xu S; Zhu Z; Cui H; Liu X
    Cell Death Dis; 2018 Feb; 9(3):260. PubMed ID: 29449532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10 mouse metastatic melanoma model.
    Mathieu V; Le Mercier M; De Neve N; Sauvage S; Gras T; Roland I; Lefranc F; Kiss R
    J Invest Dermatol; 2007 Oct; 127(10):2399-410. PubMed ID: 17495956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FTY720 and cisplatin synergistically induce the death of cisplatin-resistant melanoma cells through the downregulation of the PI3K pathway and the decrease in epidermal growth factor receptor expression.
    Ishitsuka A; Fujine E; Mizutani Y; Tawada C; Kanoh H; Banno Y; Seishima M
    Int J Mol Med; 2014 Oct; 34(4):1169-74. PubMed ID: 25109763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of mitochondrial oxidation by PDK2 inhibition reverses cisplatin resistance in head and neck cancer.
    Roh JL; Park JY; Kim EH; Jang HJ; Kwon M
    Cancer Lett; 2016 Feb; 371(1):20-9. PubMed ID: 26607904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
    Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
    Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is mda-7/IL-24 a potential target and biomarker for enhancing drug sensitivity in human glioma U87 cell line?
    Wang Q; Zhu Y; Yang P
    Anat Rec (Hoboken); 2013 Aug; 296(8):1154-60. PubMed ID: 23794295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitamin E δ-tocotrienol triggers endoplasmic reticulum stress-mediated apoptosis in human melanoma cells.
    Montagnani Marelli M; Marzagalli M; Moretti RM; Beretta G; Casati L; Comitato R; Gravina GL; Festuccia C; Limonta P
    Sci Rep; 2016 Jul; 6():30502. PubMed ID: 27461002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apoptosis and c-jun induction by cisplatin in a human melanoma cell line and a drug-resistant daughter cell line.
    Zhao R; Rabo YB; Egyházi S; Andersson A; Edgren MR; Linder S; Hansson J
    Anticancer Drugs; 1995 Oct; 6(5):657-68. PubMed ID: 8845476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activating the Wnt/β-Catenin Pathway for the Treatment of Melanoma--Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3.
    Atkinson JM; Rank KB; Zeng Y; Capen A; Yadav V; Manro JR; Engler TA; Chedid M
    PLoS One; 2015; 10(4):e0125028. PubMed ID: 25915038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of different sequences of radio- and chemotherapy in experimental models of human melanoma.
    Arienti C; Zoli W; Pignatta S; Carloni S; Paganelli G; Ulivi P; Romeo A; Menghi E; Sarnelli A; Medri L; Polico R; Silvestrini R; Tesei A
    J Cell Physiol; 2014 Oct; 229(10):1548-56. PubMed ID: 24591063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of Receptor Tyrosine Kinase EphB4 Triggers Tumor Growth and Hypoxia in A375 Melanoma Xenografts: Insights from Multitracer Small Animal Imaging Experiments.
    Neuber C; Belter B; Meister S; Hofheinz F; Bergmann R; Pietzsch HJ; Pietzsch J
    Molecules; 2018 Feb; 23(2):. PubMed ID: 29462967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The altered apoptotic pathways in cisplatin and etoposide-resistant melanoma cells are drug specific.
    Kissel CK; Schadendorf D; Röckmann H
    Melanoma Res; 2006 Dec; 16(6):527-35. PubMed ID: 17119454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methylation-Mediated Silencing of MicroRNA-211 Decreases the Sensitivity of Melanoma Cells to Cisplatin.
    Li N; Liu Y; Pang H; Lee D; Zhou Y; Xiao Z
    Med Sci Monit; 2019 Mar; 25():1590-1599. PubMed ID: 30821276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
    Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
    Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent USP10/13 antagonist spautin-1 suppresses melanoma growth via ROS-mediated DNA damage and exhibits synergy with cisplatin.
    Guo J; Zhang J; Liang L; Liu N; Qi M; Zhao S; Su J; Liu J; Peng C; Chen X; Liu H
    J Cell Mol Med; 2020 Apr; 24(7):4324-4340. PubMed ID: 32129945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melanomas reveal their nakedness: uncovered by interferon alfa.
    Arbiser JL; Bonner MY
    Arch Dermatol; 2009 May; 145(5):587-8. PubMed ID: 19451506
    [No Abstract]   [Full Text] [Related]  

  • 20. The Long Noncoding RNA MEG3 Contributes to Cisplatin Resistance of Human Lung Adenocarcinoma.
    Liu J; Wan L; Lu K; Sun M; Pan X; Zhang P; Lu B; Liu G; Wang Z
    PLoS One; 2015; 10(5):e0114586. PubMed ID: 25992654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.